Mounjaro (Tirzepatide)

What is a Generic Drug?

A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.

The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.

Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.

Coming Soon – Save up to 85%

Sign up to get exclusive coupon discounts and be the first to be notified when we have this product available.

Prescription Required

  • Product Details

    Description

    Mounjaro (tirzepatide) is an injectable medication that's used with diet and exercise to treat type 2 diabetes in adults.

    The use of Mounjaro has not been studied in patients who have had pancreatitis.

    Mounjaro should not be used in patients with type 1 diabetes.

    Directions

    Mounjaro is available in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg per 0.5 mL single-dose injectable pens.

    Follow the instructions that come with your Mounjaro prescription. Talk to your doctor or pharmacist about your questions or concerns.

    Use Mounjaro as instructed by your doctor.

    Mounjaro should be injected subcutaneously in the abdomen, thigh, or upper arm. Injection sites should be rotated with each dose.

    Mounjaro dosage:

    The recommended starting dose is to inject 2.5 mg subcutaneously once a week with or without food and increased to 5 mg subcutaneously once a week after 4 weeks of treatment. The dosage may be increased by 2.5 mg increments at 4-week intervals depending on medication response. The dose should not exceed 15 mg subcutaneously once a week.

    Ingredients

    Mounjaro contains tirzepatide, a glucose-dependent insulinotropic polypeptide receptor and glucagon-like peptide-1 receptor agonist.

    Contraindications

    Do not use Mounjaro if you or your family has a history of a type of thyroid cancer known as medullary thyroid carcinoma or if you have Multiple Endocrine Neoplasia syndrome type 2.

    Do not use Mounjaro if you are allergic to tirzepatide or any of the other ingredients or excipients contained in Mounjaro.

    Cautions

    WARNING: RISK OF THYROID C-CELL TUMORS

    • In both male and female rats, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether MOUNJARO causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined.

    • MOUNJARO is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk for MTC with the use of MOUNJARO and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with MOUNJARO. 


    WARNING: RISK OF THYROID C-CELL TUMORS

    See full prescribing information for complete boxed warning.

    • Tirzepatide causes thyroid C-cell tumors in rats. It is unknown whether MOUNJARO causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as the human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined.

    • MOUNJARO is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk of MTC and symptoms of thyroid tumors.

    • Discuss your medications, allergies, medical problems, and pregnancy or breastfeeding status with your doctor before you begin treatment with Mounjaro. 
    • Mounjaro may cause pancreatitis.
    • Mounjaro may cause low blood sugar if used with insulin or another type of medication that can lower blood sugar. Test your blood sugar levels and treat low blood sugar as your doctor has instructed.
    • Mounjaro may cause allergic reactions that can be severe. Get emergency care right away if you develop shortness of breath, swelling of your face, lips, tongue, or throat, rash, or rapid heart rate.
    • Mounjaro can cause acute kidney damage.
    • Mounjaro can cause gastrointestinal events that can be severe.
    • Mounjaro can cause acute gallbladder disease.
    • Patients who have had diabetic retinopathy should be monitored for complications or worsening of diabetic retinopathy.

    Side Effects

    The most common side effects experienced with Mounjaro include nausea, diarrhea, decreased appetite, vomiting, constipation, indigestion, and stomach pain.

    Call your doctor right away if you have side effects that bother you or won't go away.

    Looking to buy Mounjaro at a competitive price? Now you can go online and purchase it with a valid prescription at Canada Pharmacy.

    Reference:

    Mounjaro- tirzepatide injection, solution. Eli Lilly and Company; 2022.



    IMPORTANT NOTE: The above information is intended to increase awareness of health information and does not suggest treatment or diagnosis. This information is not a substitute for individual medical attention and should not be construed to indicate that use of the drug is safe, appropriate, or effective for you. See your health care professional for medical advice and treatment.

    Product Code : 13692

  • Product Reviews